Maternally administered digoxin, alone or in combination, successfully converted 13 of 14 fetuses with supraventricular tachycardia to normal sinus rhythm in utero, with all 14 surviving.
Observational (n=18)
No
Does maternally administered antiarrhythmic therapy improve rhythm conversion and survival in fetuses with supraventricular tachyarrhythmias?
Maternally administered antiarrhythmic therapy, primarily digoxin, is highly effective for in utero conversion of fetal supraventricular tachycardia to normal sinus rhythm and ensuring survival even in the presence of severe hydrops.
Supraventricular tachyarrhythmia has been encountered in 18 fetuses at the Yale-New Haven Medical Center during the past 4 years. Fourteen of these fetuses had supraventricular tachycardia and underwent in utero antiarrhythmic therapy with maternally administered digoxin either alone, or on combination with verapamil, propranolol, or procainamide. Thirteen of the 14 fetuses had successful in utero conversion of cardiac rhythm to normal sinus rhythm. The 14th patient underwent successful therapy after birth. All 14 fetuses survived despite severe fetal hydrops at the time of diagnosis in 13 of 14. The four remaining fetuses had either atrial flutter (3) or fibrillation. Two of the fetuses with atrial flutter died at birth, the 3rd survived after electrical cardioversion at birth. The fetus with atrial fibrillation converted to normal sinus rhythm and survived after maternal administration of digoxin. Using M-mode and pulsed Doppler echocardiography, the nature and electrophysiologic mechanism of the arrhythmia may be deduced. The latter information is reviewed along with the fetomaternal pharmacology of various antiarrhythmic agents to devise a rational antiarrhythmic treatment program.
Kleinman 외 (수요일)는 태아 심실 상부 빈맥에 대한 관찰 연구를 수행했습니다 (n=18). 모체가 투여한 디곡신(단독 또는 조합)은 심장 리듬을 정상 동 리듬으로 성공적으로 전환하는 데 평가되었습니다. 모체가 투여한 디곡신은 단독 또는 조합으로 심실 상부 빈맥이 있는 14명의 태아 중 13명을 정상 동 리듬으로 성공적으로 전환시켰으며, 14명 모두 생존했습니다.